Skip to main content
Premium Trial:

Request an Annual Quote

Patents Amersham, ABI Settle -- Will Reagents Be Less Expensive?

Premium

Amersham and Applied Biosystems announced the court-mediated settlement of their patent suits. Part of the settlement is an agreement to cross-license all of the patents under scrutiny in the litigation, and a co-development arrangement for some new DNA analysis technologies. Word in the industry, though neither company would comment on it, is that Amersham emerged victorious in the settlement.

The suit, which revolved around patents for energy-transfer fluorescent labeling dye technology and DNA sequencing instrumentation, began in November of 1997, filed by Amersham in a California district court.

ABI president Michael Hunka- piller said in a statement that the settlement would “provide us with access to a broader range of sequencing technology.” ABI would not comment afterward on what that range may include.

Elaine Mardis, assistant director of Washington University’s Genome Sequencing Center, hopes the settlement will mean being able to use Amersham reagents on the center’s 110 ABI 3700 sequencers. “The only thing that I suppose we’ve really not been able to do is use the Amersham chemistry with relative ease on the ABI instrument, if that’s what Mike has in mind,” she says. Reagent costs — the single highest expense in the sequencing process — are tough to compare because Amersham’s kits are less expensive but ABI’s have a better diluting factor, but Mardis says she’s “under the impression that Amersham is cheaper.”

Some users have blamed the escalating costs of ABI reagent kits on the lawsuit. Agencourt vice president and co-chief scientist Kevin McKernan says, “I bet the costs of the reagents probably reflected a little bit of the legal fees, but I don’t think our costs will be going down.”

— Meredith Salisbury

 

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.